Modulation of Interleukin-1 Transcriptional Response by the Interaction between VRK2 and the JIP1 Scaffold Protein

被引:54
作者
Blanco, Sandra [1 ]
Sanz-Garcia, Marta [1 ]
Santos, Claudio R. [1 ]
Lazo, Pedro A. [1 ]
机构
[1] Univ Salamanca, Program Oncol Traslac, Inst Biol Mol & Celular Canc, CSIC, E-37008 Salamanca, Spain
关键词
D O I
10.1371/journal.pone.0001660
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
Background: Cellular biological responses to specific stimulation are determined by a balance among signaling pathways. Protein interactions are likely to modulate these pathways. Vaccinia-related kinase-2 (VRK2) is a novel human kinase that can modulate different signaling pathways. Principal Findings: We report that in vivo, the activity of JIP1-JNK complexes is downregulated by VRK2 in response to interleukin-1 beta. Also the reduction of endogenous VRK2 with shRNA increases the transcriptional response to IL-1 beta. The JIP1 scaffold protein assembles three consecutive members of a given MAPK pathway forming signaling complexes and their signal can be modulated by interactions with regulatory proteins that remain to be identified. Knocking-down JIP1 with siRNA resulted in elimination of the AP1 transcriptional response to IL-1 beta. VRK2, a member of novel Ser-Thr kinase family, is able to stably interact with JIP1, TAK1 and MKK7, but not JNK, and can be isolated forming oligomeric complexes with different proportions of TAK1, MKK7 beta 1 and JNK. JIP1 assembles all these proteins in an oligomeric signalosome. VRK2 binding to the JIP1 signalosome prevents the association of JNK and results in a reduction in its phosphorylation and downregulation of AP1-dependent transcription. Conclusions/Significance: This work suggests that the intracellular level of VRK2 protein can modulate the flow through a signaling pathway and alter the response from a receptor that can be distributed by more than one pathway, and thus contribute to the cellular specificity of the response by forming alternative signaling complexes. Furthermore, the effect might be more general and affect other signaling routes assembled on the JIP1 scaffold protein for which a model is proposed.
引用
收藏
页数:15
相关论文
共 69 条
[1]
Signalling pathways of the TNF superfamily: A double-edged sword [J].
Aggarwal, BB .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756
[2]
Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large [J].
Beutler, Bruce ;
Jiang, Zhengfan ;
Georgel, Philippe ;
Crozat, Karine ;
Croker, Ben ;
Rutschmann, Sophie ;
Du, Xin ;
Hoebe, Kasper .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :353-389
[3]
Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1 [J].
Blanco, Sandra ;
Santos, Claudio ;
Lazo, Pedro A. .
MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (20) :7273-7283
[4]
The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines [J].
Blanco, Sandra ;
Klimcakova, Lucia ;
Vega, Francisco M. ;
Lazo, Pedro A. .
FEBS JOURNAL, 2006, 273 (11) :2487-2504
[5]
IB1 reduces cytokine-induced apoptosis of insulin-secreting cells [J].
Bonny, C ;
Oberson, A ;
Steinmann, M ;
Schorderet, DF ;
Nicod, P ;
Waeber, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (22) :16466-16472
[6]
Feedback control of the protein kinase TAK1 by SAPK2a/p38α [J].
Cheung, PCF ;
Campbell, DG ;
Nebreda, AR ;
Cohen, P .
EMBO JOURNAL, 2003, 22 (21) :5793-5805
[7]
Role of mitogen-activated protein kinase kinase kinases in signal integration [J].
Cuevas, B. D. ;
Abell, A. N. ;
Johnson, G. L. .
ONCOGENE, 2007, 26 (22) :3159-3171
[8]
Signal transduction by the JNK group of MAP kinases [J].
Davis, RJ .
CELL, 2000, 103 (02) :239-252
[9]
Scaffold proteins of MAP-kinase modules [J].
Dhanasekaran, D. N. ;
Kashef, K. ;
Lee, C. M. ;
Xu, H. ;
Reddy, E. P. .
ONCOGENE, 2007, 26 (22) :3185-3202
[10]
MAPKs: function, regulation, role in cancer and therapeutic targeting [J].
Dhanasekaran, D. N. ;
Johnson, G. L. .
ONCOGENE, 2007, 26 (22) :3097-3099